What is the current stock price of Cingulate Inc. (CING)?

As of the latest market data, Cingulate Inc. (CING) is trading at $5.76. The stock has seen a loss of -3.36% today.

Does Cingulate Inc. (CING) pay a dividend?

Based on current data, Cingulate Inc. does not have a confirmed active dividend policy.

What is the market cap of Cingulate Inc.?

The current market capitalization of Cingulate Inc. (CING) is approximately unavailable.

CING

Cingulate Inc.·Healthcare

5.76

3.356%(−0.20)

Market Closed

6.20

7.639%(+0.44)

After Hours

Last Updated: — ET

52W L: $3.2052W H: $11.89

CING NEWS

newsfilecorp.com

4d ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues to position CTx-1301 toward a potential commercial ADHD launch, with the regulatory focus now centered on manufacturing (CMC) rather than clinical performance.

invezz.com

Mar 16

Why did Cingulate stock skyrocket today?

Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPTO) cleared a key patent application for the firm's “Trimodal, Precision-Time Pulsatile Release Tablet.” This regulatory victory effectively safeguards the proprietary technology behind Cingulate's lead ADHD candidate – CTx-1301 – providing a massive boost to investor confidence as the company prepares for a transformative year.

Company Profile

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2021-12-08

Beta

-0.77

Websitewww.cingulate.com↗